Efficacy and safety of nivolumab and ipilimumab with or without chemotherapy for unresectable non-small cell lung cancer: a multicenter retrospective observational study

Efficacy and safety of nivolumab and ipilimumab with or without chemotherapy for unresectable non-small cell lung cancer: a multicenter retrospective observational study

Abstract Introduction Compared to platinum-based therapies, a combination of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) has demonstrated improved outcomes in advanced non-small cell lung cancer (NSCLC), albeit with higher rates of immune-related adverse events (irAEs). This multicenter retro...

Full description

Saved in:
Bibliographic Details
Main Authors: Toshiyuki Sumi, Yutaro Nagano, Keiki Yokoo, Tatsuru Ishikawa, Hirotaka Nishikiori, Osamu Honjo, Sayaka Kudo, Masami Yamazoe, Shun Kondoh, Makoto Shioya, Mitsuo Otsuka, Midori Hashimoto, Hayato Yabe, Yusuke Tanaka, Yuta Sudo, Masahiro Yanagi, Mamoru Takahashi, Hirofumi Chiba
Format: Article
Language:English
Published: Springer 2025-01-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Non-small cell lung cancer
Ipilimumab
Nivolumab
Immune-related adverse events
Chemotherapy
Online Access:https://doi.org/10.1007/s00262-024-03890-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-024-03890-4

Similar Items